Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from BioNTech

Gotistobart Nearly Doubled Median Survival Versus Chemotherapy in 87 Patient Lung Cancer Trial Stage, Pivotal Data Pending

Gotistobart reached 18.5 months median survival versus 10.0 months for chemotherapy in 87 previously treated squamous lung cancer patients. Pivotal data pending.

Medical Daily

BioNTech Halted a Cancer Vaccine Trial, and Genentech Says There Were More Deaths in the Vaccine Group

BioNTech terminated a Phase 2 mRNA cancer vaccine trial in colorectal cancer after monitors found a survival imbalance between the two arms.

Medical Daily

Updated COVID Shots Matched to the XFG Variant Reach Pharmacies While Federal Eligibility Guidance Remains Unsettled

FDA approved updated 2026-2027 COVID vaccines targeting XFG. Here is who qualifies, what insurance covers, and what guidance is still missing.

Medical Daily

From analysis to the latest developments in health,
read the most diverse news in one place.

BioNTech Moved Higher as the Broader Biotech Sector Hit a Post-Pandemic Peak, but BNTX Stock Needs Stronger Fundamentals to Keep Climbing

BioNTech shares moved higher as the broader biotech sector reached a post-pandemic peak, lifted by positive late-stage cancer vaccine data from peers rather than new clinical results of its own.

Barchart

Moderna, Merck's Cancer Vaccine Breakthrough Raises Hope For New Wave Of Personalized Treatments

Moderna and Merck's experimental cancer vaccine has delivered positive results in a late-stage melanoma trial, giving a major boost to personalized mRNA treatments as rivals including BioNTech and Roche pursue similar approaches.

International Business Times

‘I worry deeply about bioterrorism’: Is Europe sufficiently prepared for another pandemic?

Internationally renowned for their life-saving Covid vaccine, what is Moderna doing now? Their CEO joins us in the studio to discuss bioterrorism, pandemic preparedness and cancer treatment.

Euronews

BioNTech Maps Oncology Push, $1B Buyback and Manufacturing Cuts at AGM

BioNTech (NASDAQ:BNTX) used its virtual annual general meeting to outline a transition year marked by leadership changes, continued investment in oncology, a planned share repurchase program and a restructuring of its manufacturing network. Chairman of the Supervisory Board Helmut Jeggle said the 2

MarketBeat

Read news from The Economist, FT, and more,
with one subscription

BNTX Stock News: BioNTech Announces Layoffs as Covid-19 Revenue Slides

BioNTech shares sank yesterday as disappointing Q1 results prompted layoffs. But long-term investors still have ample reasons to load up on BNTX stock today.

Barchart

A Grim Diagnosis, but New Science Is Rewriting the Story of Pancreatic Cancer

The day draws nearer when it is no longer "a death sentence."

Reason

BioNTech Stock Plunges as Founders Leave. Should You Buy the Dip in BNTX Here?

BioNTech shares are crashing as the company posted a disappointing Q4 release and announced cofounders departure by the end of 2026. Here’s why BNTX stock is still worth buying today.

Barchart

Life-saving therapies are being delayed as research funding dries up

Letter: Dr Carol S Leonard writes that mRNA vaccines are a way forward for those with melanoma, but hopes are dashed by financial cuts

The Guardian - UK

BioNTech-Bristol Drug Shows Hope For Breast Cancer Patients With Few Options

BioNTech SE (NASDAQ:BNTX) and Bristol Myers Squibb Co. (NYSE:BMY) on Tuesday shared the first interim data from a global randomized Phase 2 trial of pumitamig (BNT327/BMS986545) plus chemotherapy for locally advanced/metastatic triple-negative breast cancer (TNBC) irrespective of PD-L1 expression levels.

Benzinga

Pfizer Is Giving Up on BioNTech. Should You Ditch BNTX Stock Now Too?

Pfizer is looking to sell its remaining stake in Covid-19 vaccine partner BioNTech. Have the good days finally come to an end?

Barchart

BioNTech Sees Higher 2025 Sales Driven By Bristol Myers Partnership

BioNTech SE (NASDAQ:BNTX) reported a third-quarter per-share loss of 14 cents (12 cents in euros) on Monday, a turnaround from earnings of 81 cents reported a year ago, missing the consensus earnings of 75 cents per share.

Benzinga

Get all your
news in one place.

100's of premium titles.
One news app.

GOBankingRates

Self-Made Millionaire Shares 5 European Stocks Every Smart Person Is Buying Now

GOBankingRates spoke with a self-made millionaire and investing expert to determine the best European stocks to consider buying in 2025.

Benzinga

Pfizer, Moderna, BioNTech Stocks Tumble After Report Of Plan To Link COVID Vaccines To Child Deaths

Shares of COVID-19 vaccine makers Pfizer Inc (NYSE:PFE), BioNTech SE ADR (NASDAQ:BNTX) and Moderna Inc (NASDAQ:MRNA) are trading lower Friday following a Washington Post report that Trump administration health officials intend to link the vaccines to 25 child deaths. This assertion is reportedly based on unverified submissions to the Vaccine…

Benzinga

BioNTech Advances On Positive Phase 3 Breast Cancer Drug Data

On Friday, BioNTech SE (NASDAQ:BNTX) and its partner Duality Biologics (Suzhou) Co., Ltd. released topline data from a Phase 3 trial in China evaluating trastuzumab pamirtecan (BNT323/DB-1303) versus trastuzumab emtansine (T-DM1) for HER2-positive unresectable or metastatic breast cancer patients who have previously received trastuzumab and a taxane-based chemotherapy.

Evening Standard

FTSE 100 edges down despite hopes of end to Russia-Ukraine war

Get all your
news in one place.

100's of premium titles.
One news app.

Evening Standard

GSK to be paid up to £370 million after patent row settles in US

CureVac – a German pharmaceutical company – settled a long-running patent dispute with rival BioNTech and Pfizer in the US on Thursday.

The Independent UK

‘Game-changing’ cancer vaccine trial to begin on NHS

The jab uses mRNA technology to train the immune system to fight cancerous cells

Evening Standard

Patients to be fast-tracked on to new head and neck cancer vaccine trial

The jab uses mRNA technology to train the immune system to fight cancer.

Benzinga

These Analysts Revise Their Forecasts On BioNTech After Q2 Results

BioNTech SE (NASDAQ:BNTX) reported a narrower loss for the second quarter on Monday.

Benzinga

BioNTech Narrows Losses, Q2 Revenue Doubles As Vaccine Collaboration Drives Growth

BioNTech SE (NASDAQ:BNTX) reported a second-quarter per-share loss of $1.82 (1.60 euros) on Monday, up from a loss of 3.36 euros reported a year ago, compared to beating the consensus loss of $2.42 per share.

Benzinga

Why Is AbbVie Stock Trading Higher On Thursday?

IGI Therapeutics SA, a wholly owned subsidiary of New York-based Ichnos Glenmark Innovation Inc., and AbbVie Inc. (NYSE:ABBV), on Thursday, announced an exclusive licensing agreement for IGI’s lead investigational asset, ISB 2001, developed using IGI’s proprietary BEAT protein platform, for oncology and autoimmune diseases.

Barchart

Is BioNTech Stock a Buy on Major $11 Billion Cancer-Drug Deal?

With BioNTech sealing a blockbuster $11 billion cancer deal with Bristol-Myers Squibb, should investors be loading up on this rising biotech star?

1 2 3 4 5

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.